Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
184
-
Total 13F shares, excl. options
-
49.3M
-
Shares change
-
-513K
-
Total reported value, excl. options
-
$1.63B
-
Value change
-
-$34.5M
-
Put/Call ratio
-
0.71
-
Number of buys
-
89
-
Number of sells
-
-99
-
Price
-
$33.10
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q1 2022
242 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q1 2022.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 184 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.3M shares
of 62.7M outstanding shares and own 78.71% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7M shares), FMR LLC (5.63M shares), VANGUARD GROUP INC (4.63M shares), Bellevue Group AG (3.05M shares), STATE STREET CORP (2.84M shares), BlackRock Inc. (2.75M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.16M shares), JPMORGAN CHASE & CO (1.61M shares), BOXER CAPITAL, LLC (1.09M shares), and JANUS HENDERSON GROUP PLC (1.03M shares).
This table shows the top 184 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.